Want to see TCRX full AI Analyst Report?
Top Page
TScan Therapeutics
(NASDAQ:TCRX)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.30
▼(-61.65% Downside)
Action:Reiterated
Date:09/11/26
The score is driven primarily by weak financial performance (persistent large losses, continued cash burn, and rising leverage) and very bearish technicals (price far below key moving averages with negative MACD). Corporate events add both runway-extending cost actions and heightened risk (program pause, delisting pressure, partnership loss), while valuation is limited by ongoing losses and no indicated dividend support.
Positive Factors
Focused Strategy
The sharp pivot concentrates scarce capital and personnel on selected solid-tumor programs while reducing operating costs. Expected savings and a cash runway extending into Q4 2027 provide more time to advance IND-enabling work, potentially improving the company’s ability to preserve pipeline value.
Negative Factors
Persistent Losses
Declining revenue combined with persistent, substantial losses shows that TScan’s current operations do not yet support self-funded development. Continued negative operating and free cash flow require ongoing cost control or external financing, limiting flexibility to pursue multiple programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused Strategy
The sharp pivot concentrates scarce capital and personnel on selected solid-tumor programs while reducing operating costs. Expected savings and a cash runway extending into Q4 2027 provide more time to advance IND-enabling work, potentially improving the company’s ability to preserve pipeline value.
Read all positive factors
TScan Therapeutics (TCRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.37M
Dividend YieldN/A
Average Volume (3M)783.70K
Price to Earnings (P/E)―
Beta (1Y)2.23
Revenue Growth2.15%
EPS Growth17.34%
CountryUS
Employees138
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.91
Shares Outstanding63,502,666
10 Day Avg. Volume1,647,541
30 Day Avg. Volume783,702
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.05
Price to Sales (P/S)12.58
P/FCF Ratio-0.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.00Price Target Upside26.58% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-1
Revenue Forecast (FY)$4.51M
TScan Therapeutics Business Overview & Revenue Model
Company Description
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment...
How the Company Makes Money
TScan Therapeutics generates revenue primarily from research and development collaboration and license agreements rather than from product sales, as it is a clinical-stage company and does not have broadly commercialized, marketed therapies. Under...
TScan Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.11M | 10.32M | 2.82M | 21.05M | 13.54M | 10.14M |
| Gross Profit | 6.42M | 7.46M | 2.82M | 21.05M | 13.54M | 10.14M |
| EBITDA | -112.04M | -124.13M | -119.74M | -80.10M | -59.91M | -45.30M |
| Net Income | -117.71M | -129.77M | -127.50M | -89.22M | -66.22M | -48.63M |
Balance Sheet | ||||||
| Total Assets | 171.45M | 228.79M | 371.12M | 272.15M | 199.09M | 188.11M |
| Cash, Cash Equivalents and Short-Term Investments | 100.16M | 152.41M | 290.11M | 192.04M | 120.03M | 161.41M |
| Total Debt | 90.89M | 94.14M | 97.38M | 92.43M | 85.98M | 6.04M |
| Total Liabilities | 102.43M | 105.67M | 130.15M | 121.28M | 99.66M | 27.33M |
| Stockholders Equity | 69.02M | 123.12M | 240.97M | 150.87M | 99.43M | 160.78M |
Cash Flow | ||||||
| Free Cash Flow | -118.44M | -139.73M | -114.65M | -64.50M | -70.73M | -58.62M |
| Operating Cash Flow | -116.28M | -135.32M | -110.82M | -61.36M | -66.50M | -48.68M |
| Investing Cash Flow | 46.87M | 109.37M | -52.61M | -60.76M | -4.22M | -9.94M |
| Financing Cash Flow | 172.00K | -336.00K | 208.76M | 135.44M | 29.36M | 189.67M |
TScan Therapeutics Technical Analysis
Negative
0.79
Price Trends
0.79
Negative
0.93
Negative
0.99
Negative
Market Momentum
-0.13
Positive
17.65
Positive
1.42
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRX, the sentiment is Negative. The current price of 0.79 is above the 20-day moving average (MA) of 0.64, below the 50-day MA of 0.79, and below the 200-day MA of 0.99, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 17.65 is Positive, neither overbought nor oversold. The STOCH value of 1.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TCRX.
TScan Therapeutics Risk Analysis
TScan Therapeutics disclosed 108 risk factors in its most recent earnings report. TScan Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TScan Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $336.28M | -4.90 | -42.80% | ― | ― | 59.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $254.43M | -1.68 | -90.30% | ― | ― | 48.20% | |
47 Neutral | $51.41M | -1.65 | -26.78% | ― | ― | 65.39% | |
42 Neutral | $359.75M | -1.46 | -87.95% | ― | -100.00% | 14.08% | |
42 Neutral | $235.42M | -0.47 | 187.62% | ― | -8.79% | -195.46% | |
41 Neutral | $22.37M | -0.35 | -108.72% | ― | 2.15% | 17.34% |
* Healthcare Sector Average
TCRX
TScan Therapeutics
0.32
-1.53
-82.86%
ZNTL
Zentalis Pharmaceuticals
3.59
2.03
130.13%
ALXO
ALX Oncology Holdings
1.90
0.72
61.02%
IKT
Inhibikase Therapeutics
2.33
0.65
38.69%
SRZN
Surrozen
19.45
8.04
70.46%
TIL
Instil Bio
7.36
-16.44
-69.08%
TScan Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
TScan Therapeutics Launches Executive Retention Incentive Program
Positive
Sep 11, 2026
On September 8, 2026, TScan Therapeutics’ Compensation Committee approved a retention program aimed at securing key personnel needed to support the company’s operations, including its in vivo solid tumor program. The initiative centers...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesRegulatory Filings and Compliance
TScan Therapeutics Restructures to Focus on Solid Tumors
Negative
Sep 2, 2026
On September 2, 2026, TScan Therapeutics announced a strategic reorganization that sharply pivots the company toward its in vivo solid tumor program, advancing PRAME- and MAGE-A4-targeted TCR-T candidates into IND-enabling work while pausing furth...
Business Operations and Strategy
TScan Therapeutics Faces Loss of Key Amgen Partnership
Negative
Aug 18, 2026
On August 12, 2026, TScan Therapeutics said that Amgen had exercised its right to terminate their May 8, 2023 research collaboration and license agreement focused on using TScan’s target discovery platform to identify T-cell antigens in Croh...
Business Operations and StrategyProduct-Related Announcements
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial
Positive
Jun 22, 2026
On June 22, 2026, TScan Therapeutics reported initial data from Cohort C of its ongoing ALLOHA Phase 1 trial evaluating TSC-101, produced with a commercial-ready manufacturing process, in patients with hematologic malignancies undergoing allogenei...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.